Login
EANO

Saturday, September 26

EANO Meeting - Saturday, September 26, 2026

Note that the programme is subject to change and will be continuously updated.
All times are in Central European Summer Time (CEST).

08:00-09:00

Meet the Experts (ME04) | Integrating IDH Inhibition in Glioma Management

Chairs: TBC, TBC

MO04.1 Expanding the Results of the INDIGO Trial: What We Have Learned (beyond the primary endpoint)
Ingo Mellinghoff, United States

MO04.2 Real-World Data: Clinical Patterns, Limitations, and Emerging Signals -
Roberta Ruda, Italy

MO04.3 IDH vaccination - when will it be ready for prime time?
Michael Platten, Germany

MO04.4 Combining IDH Inhibition/ Vaccination With Surgery, Radiotherapy, and Chemotherapy: When and How
Jona Hattangadi-Gluth, United States

Chairs: TBC, TBC

MO05.1 Supramarginal Resection in low- und high grade Glioma
Oliver Schnell, Germany

MO05.2 Advanced Neuromonitoring and Functional Mapping
Kathleen Seidel, Switzerland

MO05.3 Biomarker-stratified Surgery for Glioma
Franz Ricklefs, Germany

MO05.4 Onco & Functional Balance in  low- und high grade Glioma Surgery
Marike Broekman, Netherlands

Chairs: TBC, TBC

MO06.1 Understanding the psychology of grief and loss over the lifespan and the intersections with mental health and wellbeing
Lauren Breen, Australia

MO06.2 Neurosurgeons’ perspectives on coping with grief in everyday clinical practice
Carlos Velasquez, Spain

MO06.3 Coping with living loss in survivorship from patient perspective
Marie-Therese Gubi, Austria

MO06.4 Bereaved family members on grief throughout the glioblastoma disease trajectory
Rosanna Miller, United Kingdom

09:00-09:15 Break

09:15-10:45

Chairs: TBC, TBC

OS07.1 Integrating Local and Systemic Treatment
Giuseppe Minniti, Italy

OS07.2 Deciphering Cancer–Neuron Communication in Brain Metastasis through Functional Genomics
Vijay Tiwari, Denmark

OS07.3 Clinical and biological aspects of LMD
Adrienne Boire, United States

OS07.4 CNS Activity of Targeted Therapies for Lung Cancer Brain Metastases
TBC, -

Chairs: Anna Golebiewska, TBC

PD03.1 Drug screens in breast-to-brain metastasis models
Christel Herold-Mende, Germany

PD03.2 A closer look on technology of patient derived samples for drug discovery
Andrew Saterlee, United States

PD03.3 Pharmacoscopy for clinical decision making
Berend Snijder, Switzerland

PD03.4 Co-clinical trials for precision medicine- from ethics to technology
Anna Berghoff, Austria

10:45-11:15 Coffee break

11:15-12:45

Chairs: TBC, TBC

PC02.1 Pro: Surpramarginal resection
Lorenzo Bello, Italy

PC02.2 Contra: Supramarginal resection
Asgeir Jakola, Sweden

PC02.3 Pro: Vorasidenib for every patient with glioma IDH mutant grade 2 directly after surgery
Michael Weller, Switzerland

PC02.4 Contra: Vorasidenib for every patient with glioma IDH mutant grade 2 directly after surgery
Amelie Darlix, France

PC02.5 Pro: Radio-Chemotherapy for every patient with glioma IDH mutant grade 3
Susan Short, United Kingdom

PC02.6 Contra: Radio-Chemotherapy for every patient with glioma IDH mutant grade 3
Martin van den Bent, Netherlands

Chairs: TBC, TBC

JS04.1 Epigenetic and transcriptional landscapes bridging pediatric and adult CNS tumors
Matthew Clarke, United Kingdom

JS04.2 Translational insights from pediatric neuro-oncology: modeling, targets, and therapeutic implications for AYA and adult tumors
Johannes Gojo, Austria

JS04.3 Age as a variable in neuro-oncology: adapting treatment strategies across the molecular continuum
Maria Vinci, Italy

JS04.4 Leveraging artificial intelligence to bridge pediatric and adult CNS tumor biology
TBC, -

12:45-13:45 Lunch break

13:45-14:15

14:15-14:45

14:45-15:00 Break

15:00-16:00

Chairs: TBC

OS10.1 Segmentation
TBC, -

OS10.2 Federation
TBC, -

OS10.3 Radiogenomics
Yaewon Park, Korea

Chairs: TBC, TBC

JS05.1 Immunooncology prospective for brain tumors
Rakesh Jalali, India

JS05.2 Immunotherapy toxicities & immune-related complications
Sith Sathornsumetee, Thailand

JS05.3 Immunotherapy-related cognitive decline
TBC, -

JS05.4 Cognitive functioning in patients with CNS lymphoma receiving CAR T-cell therapy
Anne Buunk, Netherlands

16:00-16:15 Break

16:15-17:15

Chairs: TBC, TBC

PD04.1 Short introduction on technologies (SRS, nanopore, AI histology etc.), also Discussant 1 Neuropathology
Adelheid Wöhrer, Austria

PD04.2 Discussant 1 Neurosurgery
Miriam Ratliff, Germany

PD04.3 Discussant 2 Neuroradiology
TBC, -

PD04.4 Discussant 3 Neurosurgery
Todd Hollon, United States

 

 

Chairs: TBC, TBC

PD05.1 Cancer neuroscience in primary brain tumors
Varun Venkataramani, Germany

PD05.2 Cancer neuroscience in extracranial tumors & brain metastasis
Matthia Karreman, Germany

PD05.3 Human specific developmental programs provide insight into the mechanisms of cerebellar tumorigenesis
Parthiv Haldipur, United States

PD05.4 Preclinical importance of neurone-glioma synapse
TBC, -

Chairs: TBC, TBC

JS06.1 Patient-derived xenograft mouse models for CNS lymphoma
TBC, -

JS06.2 Diagnostic approaches and hurdles
TBC, -

JS06.3 Systemic therapy options and new directions
Jacoline Bromberg, Netherlands

JS06.4 CART-T and CNS lymphoma
Caroline Houillier, France

17:15-17:30 Break

17:30-18:00

18:00-19:00

19:30-23:00

EANO Evening